Viridian Therapeutics
VRDN19.7100.86% ( -0.170 )
Viridian Therapeutics (VRDN)
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to tr...
- Open
- 19.550
- High
- 20.005
- Low
- 19.290
- Prev. Close
- 19.880
- Volume
- 646.00K
- Turnover
- 12.70M
- Avg Price
- 19.661
- Bid/Ask Ratio
- --
- Amplitude
- 3.60%
- 52wk High
- 34.290
- Volume Ratio
- 0.45
- Turnover Ratio
- 0.63%
Viridian Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$36.1384.22%
Forecast & RatingStrong buy
17analysts
- Strong buy82.35%
- Buy17.65%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · 1 day ago, 09:32 AM
10:31 ETGraves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight
- Market Beat · Jul 24 at 03:58 AM
SEB Asset Management AB Makes New Investment in Viridian Therapeutics, Inc. $VRDN
- prnewswire · Jul 16 at 11:26 AM
12:25 ETRaymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)
- Market Beat · Jul 12 at 12:30 PM
Viridian Therapeutics (NASDAQ:VRDN) Lowered to Strong Sell Rating by Wall Street Zen
- Simplywall · Jul 10 at 04:18 PM
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval
- Baystreet · Jul 8 at 10:20 AM
Bombardier, Dividend 15, DRI Lead Scant Pack of Stocks at 52-Week Highs
